A novel molecular and clinical staging model to predict survival for patients with esophageal squamous cell carcinoma
Metrics: PDF 1482 views | HTML 2311 views | ?
Wei Wang1,*, Zhiwei Wang2,3,*, Jun Zhao4, Min Wei2, Xinghua Zhu5, Qi He2, Tianlong Ling3, Xiaoyan Chen6, Ziang Cao3, Yixin Zhang1, Lei Liu1, Minxin Shi1
1Department of Surgery, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
2Department of Breast, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China
3Department of Thoracic Surgery, Shanghai Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
4Department of Thoracic and Cardiovascular Surgery, The First Affiliated Hospital of Soochow University, Medical College of Soochow University, Suzhou, Jiangsu Province, China
5Department of Pathology, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
6Department of Pathology, Shanghai Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
*These authors have contributed equally to this work
Lei Liu, email: [email protected]
Minxin Shi, email: [email protected]
Keywords: esophageal squamous cell carcinoma, UBE2C, MGP, survival
Received: December 08, 2015 Accepted: July 26, 2016 Published: August 18, 2016
Current prognostic factors fail to accurately determine prognosis for patients with esophageal squamous cell carcinoma (ESCC) after surgery. Here, we constructed a survival prediction model for prognostication in patients with ESCC. Candidate molecular biomarkers were extracted from the Gene Expression Omnibus (GEO), and Cox regression analysis was performed to determine significant prognostic factors. The survival prediction model was constructed based on cluster and discriminant analyses in a training cohort (N=205), and validated in a test cohort (N=207). The survival prediction model consisting of two genes (UBE2C and MGP) and two clinicopathological factors (tumor stage and grade) was developed. This model could be used to accurately categorize patients into three groups in the test cohort. Both disease-free survival and overall survival differed among the diverse groups (P<0.05). In summary, we have developed and validated a predictive model that is based on two gene markers in conjunction with two clinicopathological variables, and which can accurately predict outcomes for ESCC patients after surgery.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.